The latest price target for Profound Medical (NASDAQ:PROF) was reported by Stifel on July 16, 2024. The analyst firm set a price target for $12.00 expecting PROF to rise to within 12 months (a possible 49.79% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Profound Medical (NASDAQ:PROF) was provided by Stifel, and Profound Medical upgraded their buy rating.

The last upgrade for Profound Medical Corp happened on July 16, 2024 when Stifel raised their price target to $12. Stifel previously had a hold for Profound Medical Corp.

The last downgrade for Profound Medical Corp happened on August 4, 2023 when Raymond James changed their price target from N/A to N/A for Profound Medical Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Profound Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Profound Medical was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.

While ratings are subjective and will change, the latest Profound Medical (PROF) rating was a upgraded with a price target of $9.00 to $12.00. The current price Profound Medical (PROF) is trading at is $8.01, which is out of the analyst’s predicted range.